92 related articles for article (PubMed ID: 7082583)
1. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
Hershko C; Grady RW; Link G
Br J Haematol; 1982 Jun; 51(2):251-60. PubMed ID: 7082583
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters.
Hershko C; Grady RW; Link G
Haematologia (Budap); 1984; 17(1):25-33. PubMed ID: 6427069
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
Hershko C; Avramovici-Grisaru S; Link G; Gelfand L; Sarel S
J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
[TBL] [Abstract][Full Text] [Related]
4. Investigation of physicochemical and in-vivo behavior of diastereomeric iron-59, gallium-68, and indium-111-EHPG trivalent metal complexes.
Madsen SL; Bannochie CJ; Martell AE; Mathias CJ; Welch MJ
J Nucl Med; 1990 Oct; 31(10):1662-8. PubMed ID: 2213190
[TBL] [Abstract][Full Text] [Related]
5. Phenolic ethylenediamine derivatives: a study of orally effective iron chelators.
Hershko C; Grady RW; Link G
J Lab Clin Med; 1984 Mar; 103(3):337-46. PubMed ID: 6699459
[TBL] [Abstract][Full Text] [Related]
6. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
Lau EH; Cerny EA; Wright BJ; Rahman YE
J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization.
Hershko C; Grady RW; Cerami A
J Lab Clin Med; 1978 Aug; 92(2):144-51. PubMed ID: 681807
[TBL] [Abstract][Full Text] [Related]
8. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs.
Johnson DK; Pippard MJ; Murphy TB; Rose NJ
J Pharmacol Exp Ther; 1982 May; 221(2):399-403. PubMed ID: 7077535
[TBL] [Abstract][Full Text] [Related]
9. A study of the chelating agent diethylenetriaminepentaacetic acid using selective radioiron probes of reticuloendothelial and parenchymal iron stores.
Hershko C
J Lab Clin Med; 1975 Jun; 85(6):913-21. PubMed ID: 1138024
[No Abstract] [Full Text] [Related]
10. UV and fluorescence spectral changes induced by neodymium binding of N,N'-ethylenebis[2-(o-hydroxyphenolic)glycine] and N,N'-di(2-hydroxybenzyl)ethylenediamine-N,N' diacetic acid.
Wang Z; Yang B
Spectrochim Acta A Mol Biomol Spectrosc; 2006 Nov; 65(3-4):946-9. PubMed ID: 16684618
[TBL] [Abstract][Full Text] [Related]
11. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.
Zevin S; Link G; Grady RW; Hider RC; Peter HH; Hershko C
Blood; 1992 Jan; 79(1):248-53. PubMed ID: 1728313
[TBL] [Abstract][Full Text] [Related]
12. Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies.
Lauffer RB; Greif WL; Stark DD; Vincent AC; Saini S; Wedeen VJ; Brady TJ
J Comput Assist Tomogr; 1985; 9(3):431-8. PubMed ID: 3989032
[TBL] [Abstract][Full Text] [Related]
13. Hepatobiliary MR contrast agents: 5-substituted iron-EHPG derivatives.
Lauffer RB; Vincent AC; Padmanabhan S; Villringer A; Saini S; Elmaleh DR; Brady TJ
Magn Reson Med; 1987 Jun; 4(6):582-90. PubMed ID: 3613958
[TBL] [Abstract][Full Text] [Related]
14. Fe(III)-EHPG and Fe(III)-5-Br-EHPG as contrast agents in MRI: an animal study.
Liu GC; Wang YM; Jaw TS; Chen HM; Sheu RS
J Formos Med Assoc; 1993 Apr; 92(4):359-66. PubMed ID: 8104585
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Fe-HBED and Fe-EHPG as hepatobiliary MR contrast agents.
Hoener B; Engelstad BL; Ramos EC; Macapinlac HA; Price DC; Johnson TR; White DL
J Magn Reson Imaging; 1991; 1(3):357-62. PubMed ID: 1802149
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures.
Lescoat G; Léonce S; Pierré A; Gouffier L; Gaboriau F
Chem Biol Interact; 2012 Jan; 195(2):165-72. PubMed ID: 22197641
[TBL] [Abstract][Full Text] [Related]
17. The development of new iron-chelating drugs. II.
Grady RW; Graziano JH; White GP; Jacobs A; Cerami A
J Pharmacol Exp Ther; 1978 Jun; 205(3):575-65. PubMed ID: 660531
[TBL] [Abstract][Full Text] [Related]
18. Rhodotorulic acid--investigation of its potential as an iron-chelating drug.
Grady RW; Peterson CM; Jones RL; Graziano JH; Bhargava KK; Berdoukas VA; Kokkini G; Loukopoulos D; Cerami A
J Pharmacol Exp Ther; 1979 Jun; 209(3):342-8. PubMed ID: 108388
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of Fe-(5-C2H5-EHPG)- as a contrast agent in MR imaging of hepatobiliary system.
Sheu RS; Liu GC; Wang YM; Jaw TS; Chen HM; Kuo YT
Kaohsiung J Med Sci; 1997 Feb; 13(2):75-85. PubMed ID: 9099045
[TBL] [Abstract][Full Text] [Related]
20. Chelating agents related to ethylenediamine bis(2-hydroxyphenyl)acetic acid (EDDHA): synthesis, characterization, and equilibrium studies of the free ligands and their Mg2+, Ca2+, Cu2+, and Fe3+ chelates.
Yunta F; García-Marco S; Lucena JJ; Gómez-Gallego M; Alcázar R; Sierra MA
Inorg Chem; 2003 Aug; 42(17):5412-21. PubMed ID: 12924915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
